Abstract
Bacterial meningitis remains a feared diagnosis that may lead to significant mortality and morbidity in both the developed and developing world; case fatality rates range from 10% to 50% among all age groups. Several vaccines are available (including the Haemophilus influenzae type B polysaccharide conjugate vaccine) that have proven effective in reducing the incidence of bacterial meningitis. Although a 23-valent pneumococcal polysaccharide vaccine has been available for some time, use of the 7-valent pneumococcal conjugate vaccine (PCV) has demonstrated a dramatic reduction in the incidence of invasive pneumococcal disease; despite the increase in the disease caused by nonvaccine-serotype strains, the success of the 7-valent PCV is noteworthy. A quadrivalent conjugate meningococcal vaccine has been available in the United States since 2005; although its true efficacy remains to be determined, there have been dramatic results with declining incidence in certain high-risk populations and in endemic areas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Wenger JD, Hightower AW, Facklam RR, et al.: Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990, 162:1316–1323.
Swartz MN: Bacterial meningitis—a view of the past 90 years. N Engl J Med 2004, 351:1826–1828.
Schuchat A, Robinson K, Wenger JD, et al.: Bacterial meningitis in the United States in 1995. N Engl J Med 1997, 337:970–976.
Wenger JD: Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada (Haemophilus influenzae type b disease and vaccination: the west). Pediatr Infect Dis 1998, 17:132–136.
Peltola H, Kayhty H, Sivonen A, et al.: Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977, 60:730–737.
Peltola H, Kayhty H, Virtane M, et al.: Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984, 310:1561–1566.
Heath PT: Haemophilus influenzae type b Conjugate Vaccines: A review of Efficacy Data (Haemophilus influenzae type B Vaccines). Pediatr Infect Dis 1998, 17:S117–S122.
Santosham M, Wolff M, Reid R, et al.: The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991, 324:1767–1772.
Ward J, Brenneman G, Letson GW, et al.: Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990, 323:1393–1401.
Eskola J, Ward J, Dagan R, et al.: Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999, 354:2063–2068.
Pichichero M, Latiolais T, Bernstein D, et al.: Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four-, and six-month-old infants (original studies). Pediatr Infect Dis 1997, 16:863–870.
Goldblatt D, Richmond P, Millard E, et al.: The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999, 180:538–541.
Granoff DM: Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001, 33(Suppl 4):S278–S287.
Schmitt HJ, Vonkries R, Hassenpflug B, et al.: Haemophilus influenzae type b disease: impact and effectiveness of Diphtheria-tetanus toxoid-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001, 20:767–774.
McConnell A, Tan B, Scheifele D, et al.: Invasive infections caused by Haemophilus influenzae serotypes in twelve Canadian IMPACT centers,1996–2001. Pediatr Infect Dis J 2007, 26:1025–1103.
Scheifele DW, Bettinger JA, Halperin SA, et al.: Ongoing Control of Haemophilus influenzae Type b Infections in Canadian Children, 2004–2007. Pediatr Infect Dis J 2008, 27:755–757.
Galil K, Singleton R, Levine OS, et al.: Reemergence of invasive Haemophilus influenzae type B disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999, 179:101–106.
Centers for Disease Control and Prevention: National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:880–885.
Takala AK, Eskola J, Leinone M, et al.: Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugated vaccine. J Infect Dis 1991, 164:982–986.
Murphy TV, Pastor P, Medley F, et al.: Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993, 122:517–523.
American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:314–318.
Centers for Disease Control and Prevention: Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR 2007, 56:1318–1320.
Black S, Shinefield H, Fireman B, et al.: Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187–195.
Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737–1746.
Jackson LA, Neuzil KM, Yu O, et al.: Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747–1755.
Tsai CJ, Griffin MR, Nuorti P, et al.: Changing epidemiology of pneumococcal meningitis after the introduction of Pneumococcal conjugate vaccine in the United States. Clin Infect Dis 2008, 46:1664–1672.
Kyaw MH, Lynfield R, Schaffner W, et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455–1463.
Bender JM, Ampofo K, Korgenski K, et al.: Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis 2008, 46:1346–1352.
Hsu HE, Shutt KA, Moore MR, et al.: Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360; 244–256.
Dagan R, Givon-Lavi N, Zamir O, et al.: Efect of a nonvalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003, 22:532–539.
Givon-Lavi N, Fraser D, Dagan R: Vaccination of daycare center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003, 22:524–531.
American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:532–536.
Pollard AJ, Levine M: Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000, 19:333–345.
Centers for Disease Control and Prevention: Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49(RR-7):13–20.
Rosenstein NE, Perkins BA, Stephens DS, et al.: The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 1999, 180:1894–1901.
Campagne G, Garba A, Fabre P, et al.: Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000, 19:144–150.
Richmond P, Borrow R, Miller E, et al.: Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569–1572.
Granoff DM, Pollard AJ: Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26:716–722.
Pichichero M, Casey J, Blatter M, et al.: Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J 2005, 24:57–62.
Rennels M, King J Jr, Ryall R, et al.: Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004, 23:429–435.
Tejedor JC, Moro M, Merino JM, et al.: Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13–14 months of age with antibody persistence up to 31 months. Pediatr Infect Dis J 2008, 27:579–588.
Vu DM, Welsch JA, Zuno-Mitchell P, et al.: Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006, 193:821–828.
Ortega-Sanchez IR, Meltzer MI, Shepard C, et al.: Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008, 46:1–13.
Centers for Disease Control and Prevention: Vaccination coverage among adolescents aged 13–17 years—United States, 2007. MMWR 2008, 57:1100–1103.
Centers for Disease Control and Prevention: Recommended immunization schedules for persons aged 0 through 18 Years—United States, 2009. MMWR 2009, 57(51):Q1–Q4.
Centers for Disease Control and Prevention: Recommended adult immunization schedule—United States, 2009. MMWR 2009, 57(53):Q1–Q4.
American Academy of Pediatrics: Summaries of infectious diseases. In Red Book: 2006 Report of the Committee on Infectious Diseases, edn 27. Edited by Pickering LK, Baker CJ, Long SS, McMillan JA. Elk Grove Village, IL: American Academy of Pediatrics; 2006:312–314, 455–457, 536–537.
Schaad UB: Chemoprophylaxis of bacterial meningitis. J Antimicrob Chemother 1985, 15:131–133.
Centers for Disease Control and Prevention: Emergence of fluoroquinolone-resistant Neisseria meningitidis—Minnesota and North Dakota, 2007–2008. MMWR Morb Mortal Wkly Rep 2008, 57:173–175.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verma, R., Fisher, M.C. Bacterial meningitis vaccines: Not just for kids. Curr Infect Dis Rep 11, 302–308 (2009). https://doi.org/10.1007/s11908-009-0045-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-009-0045-z